Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT04762277 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04762277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04762277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
April 6, 2021
Completion date
April 21, 2022
Enrollment
52 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa